Form 4: Director Linda Grais Receives Corvus Pharmaceuticals Options

Corvus Pharmaceuticals director Linda Grais was granted 15,000 stock options as part of standard equity compensation.

Summary

• Director Linda Grais received a grant of 15,000 stock options for Corvus Pharmaceuticals (CRVS) common stock.
• The options have an exercise price of $11.60 per share.
• The grant date for these options is June 11, 2026.
• The options are set to expire on June 11, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential future dilution of existing shareholders upon the exercise of these options.

Risks

• The value of the options is dependent on the future market performance of CRVS stock exceeding the $11.60 exercise price.

Future Outlook

The options vest 100% on the earlier of the first anniversary of the grant date or the date of the 2027 Annual Meeting of stockholders, contingent upon continued service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure board members remain incentivized to oversee long-term strategic growth.

Comparison to Industry Standards

• The grant of stock options to directors is consistent with standard compensation packages for small-cap biotechnology firms.
• Vesting schedules tied to annual meetings are a common practice to ensure director retention through the next cycle of shareholder voting.

Stakeholder Impact

• Minor potential dilution for existing shareholders if options are exercised.

Next Steps

• Vesting of options on the earlier of June 11, 2027, or the 2027 Annual Meeting.

Key Dates

Keywords

Corvus Pharmaceuticals, CRVS, Form 4, Insider Trading, Stock Options, Director Compensation